Skip to content

Effects of clomiphene and tamoxifen on pregnancy rate in infertile women

Effects of clomiphene and tamoxifen on pregnancy rate in infertile women with anovulation

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT201206131306N3
Enrollment
144
Registered
2012-07-10
Start date
2007-11-11
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian dysfunction, unspecified. Ovarian dysfunction, unspecified

Interventions

Intervention 1: Prescription of 2tablet ( 40mg) tamoxifenfir 5 days from day 3-7 of menstrual cycle, serial sonography in day 12-16 was done for evaluation of endometrial thickness and pattern and num
Treatment - Drugs
Prescription of 2tablet ( 40mg) tamoxifenfir 5 days from day 3-7 of menstrual cycle, serial sonography in day 12-16 was done for evaluation of endometrial thickness and pattern and number of mature fo
Prescription of 150mg clomiphen citrate for 5 days from day 3-7 of menstrual cycle, serial sonography in day 12-16 was done for evaluation endometrial thickness and pattern and number of mature follic

Sponsors

Vice chancellor for research-Guilan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
15 Years to 45 Years

Inclusion criteria

Inclusion criteria: Inclusion criterion: infertile women with ovulation disorders without other cause of infertility. Exclusion criteria: abnormal semen analysis and HSG or laparoscopy; age over 40; myoma; hyperprolactinema; FSH over12; hypothyroidism; hyperthyroidism; previous history of induction of ovulation; renal & liver disease and contraindication of clomiphen citrate and tamoxifen.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Pregnancy rate. Timepoint: End of menstural cycle. Method of measurement: Serum BhCG.

Secondary

MeasureTime frame
Abortion rate. Timepoint: End of menstrual cycle. Method of measurement: The incidence of menstrual bleeding and new.;Multigestation rate. Timepoint: End of menstrual cycle. Method of measurement: Sonography.;Ovarian hyperstimulation syndrome. Timepoint: End of menstrual cycle. Method of measurement: Clinical and ultrasound.;Side effects such as headaches, dizziness, blurred vision, nausea and vomiting. Timepoint: During the treatment cycle. Method of measurement: Ask the patient.

Countries

Iran (Islamic Republic of)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026